Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
This study is currently recruiting participants.
Verified September 2012 by Amgen
Study NCT00807859   Information provided by Amgen

First Received on December 11, 2008.   Last Updated on September 10, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Cancer
Breast Neoplasms
Breast Tumors
Cancer
Metastases
Metastatic Cancer
Oncology
Solid Tumors
Tumors
Additional conditions recognized in this trial
Neoplasm Metastasis
Neoplasms
Neoplasms, Second Primary
More general conditions related to this trial
Breast Diseases
Neoplasms by Site
Neoplastic Processes
Pathologic Processes
Skin Diseases
Additional drug interventions recognized in this trial
Capecitabine
Fluorouracil
Lapatinib
Paclitaxel
Trastuzumab
More general drug interventions related to this trial
Antimetabolites
Antimetabolites, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
Amgen


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services